FPA-151

N/A

Report date: 2026/03/19 16:57:38

Base Information

Drug NameFPA-151

Drug Alias Nameanti-CD3/anti-BCMA bispecific T-cell engager (Five Prime)FPA-151

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulatorsT cell surface glycoprotein CD3 modulators

TargetsT cell surface glycoprotein CD3Tumor necrosis factor ligand superfamily member 13

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending

Highest Status in ChinaN/A

Originator CompaniesFive Prime Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFive Prime Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A